VIR News
Archived Headlines
- Targeting infectious diseases, Vir Biotechnology raises $143 million pricing IPO at $20 low end 10/10/19
- US IPO Week Ahead: 2 billion-dollar biotechs and a bank 10/04/19
- 5 biotech IPOs are pricing tonight with 2 more on the calendar 10/02/19
- Infectious disease biotech Vir Biotechnology sets terms for $150 million IPO 09/30/19
- US IPO Weekly Recap: The fall IPO market is looking up as 10 companies launch in a 1-IPO week 09/06/19
See more
Biotech IPOs close to beating Covid-19
Less than nine months after Covid-19 became an unwelcome household word, the virus may be close to being vanquished. A number of biotech IPOs are key players in vaccine development. Most prominent is headline grabber Moderna (MRNA), which went public in...read more
US IPO Week Ahead: Another biotech plans to take on the IPO market
Biotechs are back as another early stage biotech, Keros Therapeutics (KROS), plans to take on the IPO market in the week ahead, following last week's successful debut of Zentalis Pharmaceuticals (ZNTL). ...read more
Hard times for SoftBank in the IPO market
The We Company (WE) isn’t SoftBank’s only dud. SoftBank has been a principal shareholder on two US IPOs this year, both of which are now underwater. This week’s IPO of Chinese software platform OneConnect Financial Technology...read more
US IPO Weekly Recap: Two big biotechs and a bank squeeze through the IPO window
Three IPOs raised a combined $426 million this week, all pricing below the midpoint and finishing below issue. On average they returned a disappointing -13.5%. Despite lopping $1 billion off of its proposed valuation, Germany-based BioNTech...read more